Decoy Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| March 31, 2026 | DECOY THERAPEUTICS INC. | |
|---|---|---|
| By: | /s/ Frederick E. Pierce | |
| Frederick E. Pierce | ||
| Chief Executive Officer | ||
Each of the undersigned officers and directors of Decoy Therapeutics Inc., hereby constitutes and appoints Frederick E. Pierce and Mark J. Rosenblum, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Annual Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Frederick E. Pierce | Chief Executive Officer and Director | March 31, 2026 |
| Frederick E. Pierce | (Principal Executive Officer) | |
| /s/ Mark J. Rosenblum | Chief Financial Officer | March 31, 2026 |
| Mark J. Rosenblum | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ William K. McVicar | Chairman of the Board of Directors | March 31, 2026 |
| William K. McVicar | ||
| /s/ David J. Arthur | Director | March 31, 2026 |
| David J. Arthur | ||
| /s/ Tess Burleson | Director | March 31, 2026 |
| Tess Burleson | ||
| /s/ Arnold Hanish | Director | March 31, 2026 |
| Arnold Hanish | ||
| /s/ Paul Lammers | Director | March 31, 2026 |
| Paul Lammers | ||
| /s/ Jonathan Lieber | Director | March 31, 2026 |
| Jon Lieber | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.